Phase 2b open label extension clinical study of enobosarm to prevent muscle loss
Latest Information Update: 23 Oct 2024
At a glance
- Drugs Enobosarm (Primary)
- Indications Muscular atrophy; Obesity; Overweight
- Focus Therapeutic Use
Most Recent Events
- 21 Oct 2024 According to a Veru media release, the Company will present Meta-analysis of subjects from 4 randomized clinical trials supports the potential of enobosarm to optimize weight loss, at ObesityWeek, taking place November 3-6, 2024, in San Antonio, Texas.
- 02 May 2024 According to a Veru media release, topline results of the separate blinded Phase 2b extension clinical study are expected in calendar Q2 2025.
- 25 Apr 2024 According to Veru media release, data from this trial will be presented at at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting, taking place May 9-11, 2024 in New Orleans, LA.